title: How can drug discovery for psychiatric disorders be improved?
abstract: Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.
authors.affiliation: IDRS, Suresnes, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Agid
authors.forename: György
authors.initials: G
authors.lastname: Buzsáki
authors.forename: David M
authors.initials: DM
authors.lastname: Diamond
authors.forename: Richard
authors.initials: R
authors.lastname: Frackowiak
authors.forename: Jay
authors.initials: J
authors.lastname: Giedd
authors.forename: Jean-Antoine
authors.initials: JA
authors.lastname: Girault
authors.forename: Anthony
authors.initials: A
authors.lastname: Grace
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Lambert
authors.forename: Husseini
authors.initials: H
authors.lastname: Manji
authors.forename: Helen
authors.initials: H
authors.lastname: Mayberg
authors.forename: Maurizio
authors.initials: M
authors.lastname: Popoli
authors.forename: Alain
authors.initials: A
authors.lastname: Prochiantz
authors.forename: Gal
authors.initials: G
authors.lastname: Richter-Levin
authors.forename: Peter
authors.initials: P
authors.lastname: Somogyi
authors.forename: Michael
authors.initials: M
authors.lastname: Spedding
authors.forename: Per
authors.initials: P
authors.lastname: Svenningsson
authors.forename: Daniel
authors.initials: D
authors.lastname: Weinberger
mesh_terms: D003245:Consensus Statements as Topic; D015195:Drug Design; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology; D008954:Models, Biological; D017410:Practice Guidelines as Topic; D015398:Signal Transduction / Q000187:drug effects; D011795:Surveys and Questionnaires; D014149:Tranquilizing Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D014149:Tranquilizing Agents